The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Another Agent, a triple GIP/GLP-1/GCG receptor activator, are demonstrating impressive results in improving obesity and glycemic control. Furthermore, the inclusion of NMN, a critical coenzy